Edwards Lifesciences Corporation EW
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 5.60% | 5.03% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.60% | 5.03% | |||
| Cost of Revenue | 8.22% | 5.71% | |||
| Gross Profit | 4.87% | 4.84% | |||
| SG&A Expenses | 7.47% | -13.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 22.54% | 0.70% | |||
| Total Operating Expenses | 7.73% | -5.32% | |||
| Operating Income | 0.93% | 38.36% | |||
| Income Before Tax | 13.25% | 407.74% | |||
| Income Tax Expenses | 255.56% | 198.85% | |||
| Earnings from Continuing Operations | -36.59% | 492.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -36.46% | 317.43% | |||
| EBIT | 0.93% | 38.36% | |||
| EBITDA | 1.19% | 33.98% | |||
| EPS Basic | -36.15% | 318.40% | |||
| Normalized Basic EPS | -14.77% | 30.34% | |||
| EPS Diluted | -36.15% | 329.33% | |||
| Normalized Diluted EPS | -14.73% | 30.31% | |||
| Average Basic Shares Outstanding | -0.48% | -0.21% | |||
| Average Diluted Shares Outstanding | -0.53% | -0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||